V503
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Cancers
Conditions
Cervical Cancers, Vulvar Cancer, Vaginal Cancer, Genital Lesions, PAP Test Abnormalities, HPV Infections
Trial Timeline
Aug 27, 2009 โ Apr 22, 2021
NCT ID
NCT00943722About V503
V503 is a phase 3 stage product being developed by Merck for Cervical Cancers. The current trial status is completed. This product is registered under clinical trial identifier NCT00943722. Target conditions include Cervical Cancers, Vulvar Cancer, Vaginal Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04635423 | Phase 3 | Completed |
| NCT03903562 | Phase 3 | Completed |
| NCT03158220 | Phase 3 | Completed |
| NCT01254643 | Phase 3 | Completed |
| NCT00943722 | Phase 3 | Completed |
Competing Products
20 competing products in Cervical Cancers